Cayman chemists develop a cell-active, PGD2-competitive inhibitor with low nM affinity for H-PGDS that obeys the rule of five.
- Potent, long-lived inhibition of hematopoietic prostaglandin D2 synthase (H-PGDS) has potential as a therapeutic for a variety of inflammatory diseases including asthmatic anaphylaxis, mastocytosis, rheumatoid arthritis, and Duchenne muscular dystrophy.
- KMN-010034 was identified as a low nM inhibitor of H-PGDS from a targeted series of 20 compounds evaluated by a competitive binding assay, a direct binding assay, a kinetic inhibition assay, and a cell-based ELISA.
- This novel imidazole analog displays an increase in competition with glutathione (GSH) for the H-PGDS active site, compared to amide-linker analogs previously generated from pharma programs such as Sanofi’s that are not competitive with GSH. The significance of this will be explored in a future publication.
Products Related to This Research
- Measure PGD2 in multiple sample types
- Assay 24 samples in triplicate or 36 samples in duplicate
- Measure PGD2 levels down to 55 pg/ml
- Incubation: 18 hours | Development: 90-120 minutes
| Read: Colorimetric at 405-420 nm
- Screen for inhibitors of H-PGDS
- Designed for high-throughput screening
- Includes HQL-79 as a positive control
- Plate-based fluorescence polarization measurement (ex 470 nm, em 530 nm)
Do you want to learn more about our newest supplier Cayman Chemical?
Cayman Chemical Company helps make research possible by supplying scientists worldwide with biochemical tools used to understand cancer, neurochemistry, oxidative injury, endocrinology, atherosclerosis, and other human health challenges. Their scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others for use as research reagents and qualified standards.
Please do not hesitate to contact us if you require any further information.